Bloomberg Surveillance · Tuesday, September 15, 2026
Carlyle CEO Harvey Schwartz is joining MIT's AI Impact Consortium to leverage proprietary data for making better investment choices and improving portfolio company value. He believes AI is a transformative technology that can drive breakthroughs in industry and medical science.
“So as I said before, for 15 years we've been rolling up this proprietary data. When I joined Carlyle three and a half years ago, I got very lucky. One of the things that we were working on was how to think about using machine learning to make better investment choices.”
“We think about this transformative technology really most simply in three ways. How can we run Carlyle better? How can we make better investments? How can we improve the value of the portfolio of companies?”
“I truly do believe we will see breakthroughs in industry growth. We'll see breakthroughs in medical science. I think we'll see extraordinary opportunities here with this technology. As we go through this, there are going to be moments of growing pains and nervousness. I think it's important as policymakers and the leaders of the technology themselves, and you've seen them start to do this, make sure we have the proper guardrails.”